• Wednesday, May 2, 2018 @ 12:00 am
  • Announced first-in-human study for an alpha-synuclein PET tracer for Parkinson's disease
  • Selected Tau small molecules (Tau Morphomers) have entered into IND/CTA* enabling studies; Phase 1 to commence by the end of 2018
  • Increased R&D investment and resources across our key programs
  • Financial position remains strong with CHF 109.7 million in cash, allowing the Company to be fully financed through Q2 2019, excluding potential incoming milestones

Find the full media release below.

You may also be interested in